EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 3, 2007, Pages 794-804

  Tavridou, Anna ^a   Kaklamanis, Loukas ^b   Papalois, Apostolos ^c   Kourounakis, Angeliki P ^d   Rekka, Eleni A ^e   Kourounakis, Panos N ^e   Charalambous, Avgui ^c   Manolopoulos, Vangelis G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c ELPEN Pharmaceutical Co Inc   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BIPHENYL) 4 METHYL OCTAHYDRO 1,4 BENZOXAZIN 2 OL; 2 [1 [2 [1 (3 ACETOXY 2,2 DIMETHYLPROPYL) 7 CHLORO 5 (2,3 DIMETHOXYPHENYL) 2 OXO 1,2,3,5 TETRAHYDROBENZO[E][1,4]OXAZEPIN 3 YL]ACETYL]PIPERIDIN 4 YL]ACETIC ACID; 2 [2 FLUORO 2 (QUINUCLIDIN 3 YLIDENE)ETHOXY] 9H CARBAZOLE; 5 [N [2 BUTENYL 3 (2 METHOXYPHENYL)] N METHYLAMINO] 1,1 PENTYLIDENEBIS(PHOSPHONIC ACID)TRIPIVALOYLOXYMETHYL ESTER; AMINOTRANSFERASE; CHOLESTEROL; EP 2306; ER 27856; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; TAK 475; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YM 53601;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME INHIBITION; LIPOGENESIS; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ATHEROSCLEROSIS; BIPHENYL COMPOUNDS; CHOLESTEROL, DIETARY; DIET, ATHEROGENIC; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; LIVER; MALE; MORPHOLINES; ORGAN SPECIFICITY; RABBITS;

EID: 36348939983     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.126375     Document Type: Article

References (37)

1. Alfon J, Guasch JF, Berrozpe M, and Badimon L (1999) Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening: preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 145:325-331.
2. Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, and Sugiyama Y (2003) Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 466:155-161.
3. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, and Tremoli E (2002) Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 22:692-698.
4. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, and Corsini A (1998) Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 137 (Suppl):S101-S109.
5. Burnett JR (2006) Drug evaluation: TAK-475: an oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs 7:850-856.
6. Charlton-Menys V, and Durrington PN (2007) Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 67:11-16.
7. Chrysselis MC, Rekka EA, and Kourounakis PN (2000) Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J Med Chem 43:609-612.
8. Chrysselis MC, Rekka EA, Siskou IC, and Kourounakis PN (2002) Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J Med Chem 45:5406-5409.
9. Davidson MH (2007) Squalene synthase inhibition: a novel target for the management of dyslipidemia. Cur Atheroscler Rep 9:78-80.
10. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, and Veltri E (2004) Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 58:746-755.
11. Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582.
12. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, and Galetta F (2003) A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 90:317-321.
13. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, and Gumbiner B (2002) Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90:1084-1091.
14. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, et al. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102:8132-8137.
15. Group 4S (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389.
16. Hennekens CH (1998) Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 97:1095-1102.
17. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, et al. (2003) Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57:168-177.
18. Hiyoshi H, Yanagimachi M, Ito M, Ohtsuka I, Yoshida I, Saeki T, and Tanaka H (2000) Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3- methylglutaryl-coa reductase inhibitors. J Lipid Res 41:1136-1144.
19. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, and Alberts AW (1989) Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248:498-505.
20. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J Am Med Assoc 282:2340-2346.
21. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868-874.
22. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, and Durham SK (1995) In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131:163-174.
23. Mitani H, Egashira K, Ohashi N, Yoshikawa M, Niwa S, Nonomura K, Nakashima A, and Kimura M (2003) Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Pharmacology 68:121-130.
24. Nachtigal P, Kopecky M, Solichova D, Zdansky P, and Semecky V (2005) The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 57:197-203.
25. Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, and Sugiyama Y (2003) Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 139:911-918.
26. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, and Sirtori CR (1995) Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 117:189-198.
27. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, and Yokoyama M (2001) Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154:87-96.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307.
29. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL (1989) Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924.
30. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, and von Bergmann K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943-1948.
31. Sugano M, Makino N, and Yanaga T (1996) The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 127:123-129.
32. Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2006) Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol 535:34-42.
33. Tavridou A and Manolopoulos VG (2004) Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Eur J Pharmacol 505:213-221.
34. Ugawa T, Kakuta H, Moritani H, and Inagaki O (2002a) Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br J Pharmacol 137:561-569.
35. Ugawa T, Kakuta H, Moritani H, and Shikama H (2002b) Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol 135:1572-1578.
36. Vickers AJ, and Altman DG (2001) Statistics notes: analysing controlled trials with baseline and follow up measurements. Br Med J 323:1123-1124.
37. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, and Mehta JL (1998) Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18:1433-1439.